Abstract
Hypoxia-inducible factor 1 (HIF-1) is the major transcription factor activated during hypoxia. It is composed of HIF-1α and HIF-1β subunits. While HIF-1β is constitutively expressed, HIF-1α is targeted to proteasome degradation under normoxic conditions. Under hypoxia, HIF-1α is stabilized and heterodimerizes with HIF-1β. Iron chelators have also been reported to stabilize HIF-1α protein and activate HIF-1. In this study, we investigated the effects of dibenzoylmethane (DBM), a natural dietary compound and an iron chelator, on HIF-1 pathway. We found that DBM increases HIF-1α protein levels in a dose- and time-dependent manner. This induction was accompanied with activation of HIF-1, measured by reporter gene assay and increased production of its downstream target, the vascular endothelial growth factor. Mechanistically, HIF-1α was stabilized by DBM at a step prior to ubiquitination. The effect of DBM on HIF-1 and its low toxicity profile might be therapeutically beneficial in ischemic diseases.
Original language | English (US) |
---|---|
Pages (from-to) | 279-286 |
Number of pages | 8 |
Journal | Biochemical and Biophysical Research Communications |
Volume | 303 |
Issue number | 1 |
DOIs | |
State | Published - Mar 28 2003 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology
Keywords
- Cardiomyocyte
- Dibenzoylmethane
- HIF-1α
- Prostate cancer cells
- VEGF